Alzheimers Research & Therapy

Article	Citations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	359
Immediate and long-term consequences of COVID-19 infections for the development of neurological disease	327
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval	206
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering	143
Cognitive impact of COVID-19: looking beyond the short term	140
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology	120
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment	111
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease	107
Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment	97
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia	94
Imaging biomarkers in neurodegeneration: current and future practices	89
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	86
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review	85
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease	81
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review	75
Reproducibility of EEG functional connectivity in Alzheimer’s disease	75
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes	73
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	73
Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance	68
The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease	63
The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study	62
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease	60
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	60
White matter hyperintensities across the adult lifespan: relation to age, Aβ load, and cognition	59
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals	58

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease	58
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study	57
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis	56
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two	54
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	54
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach	53
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice	53
The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease	53
Portals to frailty? Data-driven analyses detect early frailty profiles	52
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia	52
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	49
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression	49
Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment	48
A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse	48
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	48
The Alzheimer’s disease drug development landscape	48
Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis	47
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J	47
Repurposed agents in the Alzheimer’s disease drug development pipeline	47
One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”	47
In vivo tau pathology is associated with synaptic loss and altered synaptic function	46
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease	46
Retinal microvasculature dysfunction is associated with Alzheimer’s disease and mild cognitive impairment	46
Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia	46
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome	45
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort	43
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration	43
Improving the resistance and resilience framework for aging and dementia studies	41
Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies	41
Relevance of biomarkers across different neurodegenerative diseases	40
Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases	40
Alzheimer’s disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles	40
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	40
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery	40
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease	39
GPS driving: a digital biomarker for preclinical Alzheimer disease	39
The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study	39
Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review	39
EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease	39
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease	38
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease	38
Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease	37
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6	37
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease	36
The insulin resistance by triglyceride glucose index and risk for dementia: population-based study	36
Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration	36
Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer’s dementia	36
Melatonin levels in the Alzheimer’s disease continuum: a systematic review	36
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6	35
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative	35

Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer’s disease created by integrative analysis of multi-omics data	35
Enhancing magnetic resonance imaging-driven Alzheimer’s disease classification performance using generative adversarial learning	35
Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40	34
Are ketogenic diets promising for Alzheimer’s disease? A translational review	34
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias	33
Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics	33
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease	33
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review	33
Predict Alzheimer’s disease using hippocampus MRI data: a lightweight 3D deep convolutional network model with visual and global shape representations	33
Herpesvirus infections and Alzheimer’s disease: a Mendelian randomization study	33
Glucose metabolism and AD: evidence for a potential diabetes type 3	33
Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer’s disease and controls	33
Associations between social and intellectual activities with cognitive trajectories in Chinese middle-aged and older adults: a nationally representative cohort study	32
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease	32
Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes	32
Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer’s disease	32
Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study	32
Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals	32
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?	32
An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease	32
RETRACTED ARTICLE: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis	31
Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population	31
Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again?	31
Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer’s disease	31
The short-term effects of sedentary behaviour on cerebral hemodynamics and cognitive performance in older adults: a cross-over design on the potential impact of mental and/or physical activity	31
TREM2 Alzheimer’s variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages	31
Detection of dementia on voice recordings using deep learning: a Framingham Heart Study	30
Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer’s disease with an implantable ultrasound device	30
Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer’s disease patients	30
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease	30
Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer’s disease	29
MIND diet and the risk of dementia: a population-based study	29
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials	29
Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum	29
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline	28
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	28
In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases	28
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease	28
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy	28
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project	28
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study	28
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrie	28
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease	27
The efficacy of exergaming in people with major neurocognitive disorder residing in long-term care facilities: a pilot randomized controlled trial	27
The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease	27
Apolipoprotein E and sex modulate fatty acid metabolism in a prospective observational study of cognitive decline	27
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach	27
Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network	26
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease	26
Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning	26
Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice	25
Distinct network topology in Alzheimer’s disease and behavioral variant frontotemporal dementia	25
Trichostatin A ameliorates Alzheimer’s disease-related pathology and cognitive deficits by increasing albumin expression and Aβ clearance in APP/PS1 mice	25
Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain	25
Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration	25
The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer’s disease	25
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6	25
Early detection of amyloid load using 18F-florbetaben PET	25
White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer’s disease	25
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease	24
FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels	24
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review	24
Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer’s disease	24
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction	24
The two faces of synaptic failure in AppNL-G-F knock-in mice	24
Use of the Clock Drawing Test and the Rey–Osterrieth Complex Figure Test-copy with convolutional neural networks to predict cognitive impairment	24
Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes	23
Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study	23
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study	23
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	23
Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systemati	23
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults	23
The dynamics of plasma biomarkers across the Alzheimer’s continuum	22
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration	22
Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea	22
Perspectives and challenges in patient stratification in Alzheimer’s disease	22
Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia	22
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	22
Verbal intelligence is a more robust cross-sectional measure of cognitive reserve than level of education in healthy older adults	22
Race, APOE genotypes, and cognitive decline among middle-aged urban adults	22

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study	22
Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer’s disease	22
Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers	21
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	21
Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies	21
Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission	21
Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model	21
Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease	20
Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia	20
The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease	20
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease	20
Associations between vascular risk factors and subsequent Alzheimer’s disease in older adults	20
Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE	20
Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning	20
Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis	20
Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study	20
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	20
Association between physical activity and conversion from mild cognitive impairment to dementia	19
Serum neurofilament light chain level as a predictor of cognitive stage transition	19
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology	19
Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results	19
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease	19
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation	19
Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study	19
Associations between locus coeruleus integrity and nocturnal awakenings in the context of Alzheimer’s disease plasma biomarkers: a 7T MRI study	19
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease	19
Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study	19
The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone	18
An analysis of genetically regulated gene expression across multiple tissues implicates novel gene candidates in Alzheimer’s disease	18
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease	18
Role of liraglutide in Alzheimer’s disease pathology	18
COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients	18
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology	18
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease	18
Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease	18
27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial	18
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217	18
Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer’s disease GWAS and self-report proxy phenotype GWAX	18
Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project	18
Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice	18
Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD	17
Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations	17
Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults	17
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	17
Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions	17
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients	17
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts	17
Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer’s disease and vascular cognitive impairment	17
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study	17
High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial	17
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease	17
Genetically determined blood pressure, antihypertensive medications, and risk of Alzheimer’s disease: a Mendelian randomization study	17
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease	17